UCSD Spinout Antiva Biosciences Gets $22M

Antiva Biosciences, a U.C. San Diego biopharmaceuticals spinout targeting treatments for pre-cancerous lesions caused by human papilloma virus (HPV) infection, said it has raised $22M in a Series C funding. The funding was led by Brace Pharma Capital, an also included NS Investment, Osage University Partners and Alexandria Venture Investments, plus Canaan Partners and Sofinnova Ventures. Vinzenz Ploerer of Brace Pharma has joined the company's board with the new funding. Antiva Biosciences in based in South San Francisco, but was founded in 2012 by Dr. Karl Hostetler of The University of California San Diego. Hostetler is Professor of Medicine Emeritus, UCSD School of Medicine, along with serving as Director, San Diego VA Medical Center Endocrinology Clinic, and Associate Member, Rebecca and John Moores Cancer Center, UCSD. More information »